(-0.22%) 5 201.25 points
(-0.19%) 39 120 points
(-0.29%) 18 134 points
(0.99%) $79.77
(-1.23%) $2.16
(-0.15%) $2 318.80
(1.07%) $27.90
(0.56%) $990.10
(0.19%) $0.932
(0.30%) $10.92
(0.35%) $0.803
(1.15%) $92.79
Quarter results today
(bmo 2024-05-09)
Expected move: +/- 12.75%
Live Chart Being Loaded With Signals
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U...
Stats | |
---|---|
Šios dienos apimtis | 3.30M |
Vidutinė apimtis | 2.54M |
Rinkos kapitalizacija | 209.32M |
EPS | $0 ( 2024-05-08 ) |
Kita pelno data | ( $-0.0600 ) 2024-08-08 |
Last Dividend | $0.0700 ( 2014-04-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.04 |
ATR14 | $0.00800 (0.56%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-02 | Rankowitz Michael L | Buy | 90 000 | Common Stock Option |
2023-10-02 | Eisenberger Mario | Buy | 70 000 | Common Stock Option |
2023-10-02 | Lu Lucy | Buy | 80 000 | Common Stock Option |
2023-10-02 | Hyun Grace | Buy | 60 000 | Common Stock Option |
2023-05-09 | Greco Michele | Buy | 104 000 | Common Stock Option |
INSIDER POWER |
---|
94.85 |
Last 100 transactions |
Buy: 7 521 942 | Sell: 795 000 |
Tūris Koreliacija
Veru Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
AGLE | 0.927 |
MESO | 0.915 |
CNSP | 0.911 |
PRTK | 0.91 |
STER | 0.91 |
AZYO | 0.906 |
MOTNU | 0.897 |
BRY | 0.896 |
TCX | 0.895 |
TTGT | 0.894 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
LWAC | -0.95 |
FANH | -0.894 |
AGFS | -0.892 |
ATHN | -0.892 |
ARIZ | -0.888 |
IMRA | -0.883 |
SDC | -0.883 |
RNDV | -0.878 |
SAGE | -0.872 |
TGLS | -0.867 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Veru Inc Koreliacija - Valiuta/Žaliavos
Veru Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $16.30M |
Bruto pelnas: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2023 |
Pajamos: | $16.30M |
Bruto pelnas: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2022 |
Pajamos: | $39.35M |
Bruto pelnas: | $30.59M (77.73 %) |
EPS: | $-1.050 |
FY | 2021 |
Pajamos: | $61.26M |
Bruto pelnas: | $47.93M (78.24 %) |
EPS: | $0.100 |
Financial Reports:
No articles found.
Veru Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2010-01-27 |
Last Dividend | $0.0700 | 2014-04-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-05-07 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.040 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.68 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.200 | 4.14% |
2011 | $0.200 | 3.50% |
2012 | $0.230 | 4.87% |
2013 | $0.270 | 3.69% |
2014 | $0.140 | 1.67% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.65 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.498 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.960 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.72 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.92 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0454 | -1.500 | 9.24 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -36.63 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.406 | 2.00 | -0.135 | -0.271 | [0 - 30] |
freeCashFlowPerShareTTM | -0.409 | 2.00 | -0.205 | -0.409 | [0 - 20] |
debtEquityRatioTTM | 0.0722 | -1.500 | 9.71 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.341 | 1.000 | 7.64 | 7.64 | [0.2 - 0.8] |
operatingProfitMarginTTM | -2.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -18.24 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.188 | 0.800 | -2.08 | -1.665 | [0.5 - 2] |
Total Score | -0.970 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.85 | 1.000 | -0.692 | 0 | [1 - 100] |
returnOnEquityTTM | -0.960 | 2.50 | -7.57 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.409 | 2.00 | -0.136 | -0.409 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.406 | 2.00 | -0.135 | -0.271 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.229 | 1.500 | 5.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -4.41 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.353 |
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.